REG - Genedrive PLC - Total Voting Rights

GenedriveAnnouncement

04/08/2023 16:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230804:nRSD4022Ia&default-theme=true

RNS Number : 4022I  Genedrive PLC  04 August 2023

genedrive plc

("genedrive" or the "Company")

 

Application for Listing

 

Total Voting Rights

 

genedrive plc (AIM:GDR), the point of care molecular diagnostics company,
confirms that in order to support the further drawdown and delivery of its
£5M Equity Prepayment facility that was announced on 31 March 2023,
application has been made for the Admission to trading on AIM of 3,050,000 new
Ordinary Shares of 1.5p each ("New Ordinary Shares").  Admission of the New
Ordinary Shares ("Admission") is expected to occur on 10 August 2023.
Following Admission, the New Ordinary Shares will rank pari passu in all
respects with the Company's existing ordinary shares.

 

Following Admission the Company's issued share capital will consist of
102,099,946 Ordinary Shares of 1.5p each and this figure may be used by
shareholders as the denominator for the calculations by which they should
determine if they are required to notify their interest in, or change to their
interest in, the Company under the FCA's Disclosure Guidance and Transparency
Rules.

 

 

For further details please contact:

 

 genedrive plc                                       +44 (0)161 989 0245
 David Budd: CEO / Russ Shaw: CFO

 Peel Hunt LLP (Nominated Adviser and Joint Broker)  +44 (0)20 7418 8900
 James Steel / Patrick Birkholm

 finnCap (Joint Broker)                              +44 (0)20 7220 0500
 Geoff Nash

 Walbrook PR Ltd (Media & Investor Relations)        +44 (0)20 7933 8780 or genedrive@walbrookpr.com
                                                     (mailto:genedrive@walbrookpr.com)
 Paul McManus / Anna Dunphy                          +44 (0)7980 541 893 / +44 (0)7876 741 001

 

 

About genedrive plc (http://www.genedriveplc.com
(http://www.genedriveplc.com/) )  genedrive plc is a molecular diagnostics
company developing and commercialising a low cost, rapid, versatile, simple to
use and robust point of need molecular diagnostics platform for the diagnosis
of infectious diseases and for use in patient stratification (genotyping),
pathogen detection and other indications. The company are currently developing
a genetic test for CYP2C19 metaboliser status.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRNKQBDNBKDPFK